Low-dose Naltrexone for Post-COVID Fatigue Syndrome
Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study aims to determine if low-dose naltrexone (LDN) reduces fatigue, improves related
symptoms, and reduces inflammatory markers in peripheral blood in cases with Post-COVID-19
Fatigue Syndrome (PCFS) from COVID-19 (i.e. confirmed SARS-CoV-2 case) in the past 3-6
months. LDN refers to naltrexone given in doses of 1-4.5 mg. Overall, studies have found that
LDN is safe and well-tolerated. It may help to reduce pain and inflammation and improve
well-being and immune function.The trial will be conducted by the Complex Chronic Diseases
Program (CCDP) at BC Women's Hospital and the Post-COVID Recovery Clinics (PCRC) in British
Columbia and will demonstrate whether LDN could benefit a large number of people with PCFS.
Phase:
Phase 2
Details
Lead Sponsor:
Luis Nacul
Collaborators:
BC Women's Hospital & Health Centre Canadian Institutes of Health Research (CIHR) Fraser Health Providence Health & Services Provincial Health Services Authority University of British Columbia Vancouver Coastal Health